The Irish Times Reports on CV6’s Cancer Drug Development
In November 2022, The Irish Times reported on CV6 Therapeutics’ investment in clinical trials and further development of its lead cancer drug, CV6-168. The article, by business journalist Ciara O’Brien, highlights support from Invest Northern Ireland and investors including QUBIS, Techstart and Clarendon, alongside plans to create additional cancer research jobs in Belfast. It also explores CV6-168’s potential to work alongside standard cancer therapies and outlines the planned Phase 1a study to assess safety, dosing and early indications of anti-cancer activity.
More News
View allCV6 Therapeutics Featured in the NI Edition of the 12 Clusters of Tech
CV6 Therapeutics, have been featured in the November 2020 special report on the ‘12 Clusters of Tech’, a national campaign to champion leading clusters of UK technology led by the UK Tech Cluster Group and London Tech Week.
News Letter Highlights Invest NI’s Support for CV6’s Cancer Research
The News Letter covers the funding, university collaboration and planned research jobs supporting CV6-168’s development and preparations for its first human trial.